Company news: RealAge and HealthPrize; AstraZeneca and Daiichi Sankyo; Shire
AstraZeneca signed a co-promotion agreement for denosumab in Japan with Daiichi Sankyo, pending approval of the drug for the treatment of bone disorders stemming from bone metastasis. Daiichi Sankyo acquired rights to the drug in Japan from Amgen in 2011 and filed for approval there in 2010.
Shire is launching a scholarship program for college students with ADHD. The Shire ADHD Scholarship Program includes a monetary award and a prepaid year of ADHD coaching services provided in partnership with Seattle nonprofit the Edge Foundation make the transition to college, vocational or technical school.